ClinicalTrials.gg
CompletedNCT05936138Updated Jun 9, 2026Results posted

A Phase 1, Parallel, Single-Dose, Open-Label, Single-Period Study of LY3502970 in Participants With Normal Renal Function and Participants With Renal Impairment.

A Phase 1 interventional study of LY3502970 in Renal Insufficiency and Healthy, sponsored by Eli Lilly and Company. Completed at 4 sites in United States. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-09.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies in Renal Insufficiency by Eli Lilly and Company — 1 open to participants now, 2 under way, none of them phase 3. Renal Insufficiency · Eli Lilly and Company.

Enrollment
10th of 12
24 · median 30
Started
2023
with 2 others
Phase 1
12 of 12
1 open now
Registered
7th of 12
by date

Among the 12 studies in Renal Insufficiency by Eli Lilly and Company, this one is the 10th largest by enrollment, is one of 3 that started in 2023, is one of 12 in phase 1, and was the 7th registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 145 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

1 of the 12 studies in Renal Insufficiency by Eli Lilly and Company is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 91 Renal Insufficiency studies recruiting now, 48 (53%) set no upper age limit and 18 (20%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Renal Insufficiency by Eli Lilly and Company, or all of them as a file.
02

Study summary

The main purpose of this study is to assess the amount of study drug (LY3502970) that reaches the bloodstream and the time it takes for the body to get rid of it when given to participants with renal (kidney) impairment compared to participants with normal renal function. The safety and tolerability of LY3502970 will also be evaluated in these participants. The study will last up to 6 weeks including screening period.

03

Conditions studied

  • Renal Insufficiency
  • Healthy

Browse trials for

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a within the range 18.5 to 42.0 kilograms per meter squared (kg/m²), inclusive.
  • Men and women who agree to use highly effective or effective methods of may participate in this trial.

Participants with Normal Renal Function:

  • Healthy males or females as determined by medical history, physical examination, and other screening procedures, with normal renal function. Have estimated (eGFR) of greater than or equal to 90 milliliter per minute (mL/min)

Participants with Renal Impairment:

  • Severe renal impairment: Have eGFR of 15 to 29 mL/min and not requiring hemodialysis.
  • ESRD: Participants who have been on a stable hemodialysis schedule for at least 3 months prior to planned dosing.

Exclusion criteria

Exclusion Criteria:

  • Have a current, functioning organ transplant. Non-functional renal allografts may be allowed.
  • Regularly use known drugs of abuse or show positive findings on urinary drug screen that are not otherwise explained by permitted concomitant medications.
  • Have known allergies to LY3502970, related compounds, or any components of the formulation, or history of severe atopy.
  • Are lactating, pregnant, or intend to become pregnant, or to breastfeed during the study.
  • Have a history or presence of chronic or acute pancreatitis

Participants with Renal Impairment:

  • Have \<8.5 g/dL.
  • Participants with Type 2 Diabetes Mellitus if they have taken any Glucagon-like Peptide-1 Receptor Agonists (GLP1-RA) or a Dipeptidyl Peptidase 4 (DPP4) inhibitor in the past 6 weeks or 5 half-lives prior to dosing, whichever is longer, prior to dosing on Day 1
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    LY3502970 (Normal Renal Function)

    A single oral dose of 1 milligram (mg) LY3502970 was administered to participants with normal renal function \[defined as an estimated glomerular filtration rate (eGFR: ≥ 90 milliliters per minute (mL/min), and without a diagnosis of type 2 diabetes mellitus (T2D)\] on day 1.

    Drug: LY3502970

  • Experimental
    LY3502970 (Severe Renal Impairment)

    A single oral dose of 1 mg LY3502970 was administered to participants with severe renal function \[defined as an eGFR: 15-29 mL/min and not requiring hemodialysis, with a diagnosis of T2D\] on day 1.

    Drug: LY3502970

  • Experimental
    LY3502970 (End-Stage Renal Disease)

    A single oral dose of 1 mg LY3502970 was administered to participants with end stage renal disease \[defined as an eGFR: less than 15 mL/min or requiring hemodialysis, with a diagnosis of T2D\] on day 1.

    Drug: LY3502970

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC0-∞) of LY3502970

    PK: (AUC0-∞) of LY3502970 is reported.

    Time frame: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours postdose

  2. PK: Area Under the Concentration Versus Time Curve From Time Zero to Last Time Point (AUC0-tlast) of LY3502970

    PK: AUC0-tlast of LY3502970 is reported.

    Time frame: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours postdose

  3. PK: Maximum Observed Concentration (Cmax) of LY3502970

    PK: Cmax of LY3502970 is reported.

    Time frame: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours postdose

07

Results

Posted Jun 9, 2026

Participant flow

Participant flow — Overall Study
MilestoneLY3502970 (Normal Renal Function)LY3502970 (Severe Renal Impairment)LY3502970 (End-Stage Renal Disease)
Started1068
Completed967
Not completed101
Withdrew: Inadvertent enrollment100
Withdrew: Withdrawal by subject001

Outcome measures

PrimaryPharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC0-∞) of LY3502970

PK: (AUC0-∞) of LY3502970 is reported.

Time frame:
Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours postdose
Reported as:
Geometric mean · nanogram*hour per milliliter (ng*hr/mL)
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC0-∞) of LY3502970
nanogram*hour per milliliter (ng*hr/mL)LY3502970 (Normal Renal Function)LY3502970 (Severe Renal Impairment)LY3502970 (End-Stage Renal Disease)
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC0-∞) of LY3502970113 ± 32.1167 ± 48.6108 ± 87.8
PrimaryPK: Area Under the Concentration Versus Time Curve From Time Zero to Last Time Point (AUC0-tlast) of LY3502970

PK: AUC0-tlast of LY3502970 is reported.

Time frame:
Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours postdose
Reported as:
Geometric mean · ng*hr/mL
PK: Area Under the Concentration Versus Time Curve From Time Zero to Last Time Point (AUC0-tlast) of LY3502970
ng*hr/mLLY3502970 (Normal Renal Function)LY3502970 (Severe Renal Impairment)LY3502970 (End-Stage Renal Disease)
PK: Area Under the Concentration Versus Time Curve From Time Zero to Last Time Point (AUC0-tlast) of LY350297098.9 ± 32.9120 ± 48.990.2 ± 79.7
PrimaryPK: Maximum Observed Concentration (Cmax) of LY3502970

PK: Cmax of LY3502970 is reported.

Time frame:
Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours postdose
Reported as:
Geometric mean · nanogram per millilitre (ng/mL)
PK: Maximum Observed Concentration (Cmax) of LY3502970
nanogram per millilitre (ng/mL)LY3502970 (Normal Renal Function)LY3502970 (Severe Renal Impairment)LY3502970 (End-Stage Renal Disease)
PK: Maximum Observed Concentration (Cmax) of LY35029705.01 ± 20.76.01 ± 54.94.29 ± 67.3

Adverse events

Collected over Baseline through follow-up (Up to 12 Days). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LY3502970 (Normal Renal Function)0/10 (0%)0/10 (0%)0/10 (0%)
LY3502970 (Severe Renal Impairment)0/6 (0%)0/6 (0%)2/6 (33.3%)
LY3502970 (End-Stage Renal Disease)0/8 (0%)0/8 (0%)6/8 (75%)
Most frequent other events
Most frequent other events
EventLY3502970 (Normal Renal Function)LY3502970 (Severe Renal Impairment)LY3502970 (End-Stage Renal Disease)
HaemodialysisSurgical and medical procedures0/100/65/8
NauseaGastrointestinal disorders0/101/61/8
VomitingGastrointestinal disorders0/101/61/8
Amylase increasedInvestigations0/101/60/8
Lipase increasedInvestigations0/101/60/8
HypoglycaemiaMetabolism and nutrition disorders0/101/60/8
DiarrhoeaGastrointestinal disorders0/100/61/8

Baseline characteristics

All enrolled participants.

Age, Continuous
Age, Continuous(years)LY3502970 (Normal Renal Function)LY3502970 (Severe Renal Impairment)LY3502970 (End-Stage Renal Disease)Total
Mean58.6 ± 6.5461.7 ± 17.0753.8 ± 10.4257.8 ± 11.09
Sex: Female, Male
Sex: Female, Male(Participants)LY3502970 (Normal Renal Function)LY3502970 (Severe Renal Impairment)LY3502970 (End-Stage Renal Disease)Total
Female2204
Male84820
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)LY3502970 (Normal Renal Function)LY3502970 (Severe Renal Impairment)LY3502970 (End-Stage Renal Disease)Total
Hispanic or Latino3137
Not Hispanic or Latino75416
Unknown or Not Reported0011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)LY3502970 (Normal Renal Function)LY3502970 (Severe Renal Impairment)LY3502970 (End-Stage Renal Disease)Total
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American3148
White75315
More than one race0000
Unknown or Not Reported0011
Region of Enrollment
Region of Enrollment(Participants)LY3502970 (Normal Renal Function)LY3502970 (Severe Renal Impairment)LY3502970 (End-Stage Renal Disease)Total
United States106824
08

Study locations

4 sites
  • Clinical Pharmacology of Miami
    Miami, Florida 33014, United States
  • Advanced Pharma CR, LLC
    Miami, Florida 33147, United States
  • Orlando Clinical Research Center
    Orlando, Florida 32809, United States
  • Alliance For multispecialty Research, LLC
    Knoxville, Tennessee 37920, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2023 to primary completion in Apr 2024, 8 months.

Results were first posted in Jun 2026, 2 years 1 month after primary completion.

Of 212 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 8 months is close to that.

Counting every sponsor, half of 230 studies reached it within 8 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2023
First posted
Jul 7, 2023
StartActual
Jul 13, 2023
Primary completionActual
Apr 11, 2024
CompletionActual
Apr 11, 2024
Results first posted
Jun 9, 2026
Last update
Jun 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05936138
Responsible party
Sponsor
First posted
Jul 7, 2023
Start date
Jul 13, 2023
Primary completion
Apr 11, 2024
Completion
Apr 11, 2024
Results posted
Jun 9, 2026
Last update
Jun 9, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Orforglipron

Start the discussion